Francesca Coperchini1
Laura Croce1,2
Gianluca Ricci1Flavia Magri1,2
Mario Rotondi1,2Marcello Imbriani3
Luca Chiovato1,2*- 1Laboratory for Endocrine Disruptors, Unit of Internal Medicine and Endocrinology, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy
- 2Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
- 3Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy
Per- and polyfluoroalkyl substances (PFAS) represent a group of synthetic compounds widely used in industry plants due to their low grade of degradation, surfactant properties, thermic and flame resistance. These characteristics are useful for the industrial production, however they are also potentially dangerous for human health and for the environment. PFAS are persistent pollutants accumulating in waters and soil and recoverable in foods due to their release by food packaging. Humans are daily exposed to PFAS because these compounds are ubiquitous and, when assimilated, they are difficult to be eliminated, persisting for years both in humans and animals. Due to their persistence and potential danger to health, some old generation PFAS have been replaced by newly synthesized PFAS with the aim to use alternative compounds presumably safer for humans and the environment. Yet, the environmental pollution with PFAS remains a matter of concern worldwide and led to large-scale epidemiological studies both on plants’ workers and on exposed people in the general population. In this context, strong concern emerged concerning the potential adverse effects of PFAS on the thyroid gland. Thyroid hormones play a critical role in the regulation of metabolism, and thyroid function is related to cardiovascular disease, fertility, and fetal neurodevelopment. In vitro, ex vivo data, and epidemiological studies suggested that PFASs may disrupt the thyroid hormone system in humans, with possible negative repercussions on the outcome of pregnancy and fetal-child development. However, data on the thyroid disrupting effect of PFAS remain controversial, as well as their impact on human health in different ages of life. Aim of the present paper is to review recent data on the effects of old and new generation PFAS on thyroid homeostasis. To this purpose we collected information from in vitro studies, animal models, and in vivo data on exposed workers, general population, and pregnant women.
Introduction
Per- and polyfluoroalkyl substances (PFAS) are a family of synthetic chemicals widely used in industry. The first PFAS were invented in the 1930s and used in the production of non-stick and waterproof coatings, according to the Interstate Technology & Regulatory Council (ITRC). Nowadays, more than 3,000 synthetic compounds are classified as PFAS. They have wide-ranging applications, such as Teflon, food packaging, grease-resistant microwave-food bags, carpets that resist stains, stain-resistant furniture, fire foaming, and pipes and wires that resist corrosion (1, 2).
PFAS are organic substances composed by a chain of carbon atoms (in variable number, from 4 to 16) linked to fluorine atoms. A functional group at the end of the chain essentially distinguishes the various compounds of this family from one another. PFAS are generally classified in long- and short-chain compounds due to the presence of more than six (long-chain) or less than eight (short-chain) carbons (1, 3, 4). Carbon-fluorine bonds are among the strongest chemical bonds in organic chemistry. Thank to this bond, PFAS resist degradation and persist not only in the environment, but also in the human and animal body from which they are difficult to be eliminated. PFAS are not flammable and not corrosive, they do not burn, degrade, or react with other chemicals. In general, PFAS chemicals have a hydrophobic head and a hydrophobic tail (1, 3, 4).
PFAS have been frequently reported to contaminate surface water, groundwater, and soil. Indeed, given their persistence and mobility, they do not break down in environmental matrices and can move through soil to drinking water (2, 5, 6). This implies that if PFAS release will not be stopped, they will continue to accumulate in the environment, drinking water, and food, thus becoming global environmental pollutants potentially threating the human health and wildlife (2). As assessed by a biomonitoring approach, the concentration of PFAS in blood samples follows an overall order as: serum > plasma > whole blood (2). Geographical variations in blood PFAS concentration results from dietary intake, drinking water, dust, and industrialization level of the investigated area. In human blood, the concentration of PFAS appears to be associated with age, gender, and other factors, including dietary habits, lifestyle, family income, education level, social status, and body mass index (2). PFAS levels in human milk are overall much lower than those in human blood, likely due to low transfer rate of these chemicals from mother’s blood to breast milk. To date, studies remain limited on the use of human hair or nails as a non-invasive approach for PFAS biomonitoring (2).
PFAS can have several detrimental effects of endocrine function including the thyroid one. PFAS were recognized, among the potential adverse role on human health, as endocrine disruptors. In our previous review we reported the main findings regarding the potential adverse effects of PFAS on thyroid gland taking into account studies until 2017, evidencing controversial data about PFAS action on thyroid hormones both in in vitro studies and on different type of subjects (7). Thyroid hormones (TH) are involved in several biological processes, which include regulation of energy expenditure, growth, and neurodevelopment, starting from intrauterine life throughout infancy. Moreover, they regulate metabolic processes also in adult life (8–10).
During fetal life, thyroid hormones are crucial for normal brain development, being essential for orchestrating the processes of neurogenesis, migration, synaptogenesis, and myelination (8–10). Indeed, insufficient thyroid hormone levels at critical times of human neurodevelopment can induce long-term intellectual and behavioral impairments (8–10). Moreover, after birth and during all stages of infancy and adult life, TH regulate metabolism primarily through actions in the brain, white fat, brown fat, skeletal muscle, liver, and pancreas. TH are secreted through the hypothalamic–pituitary–thyroid axis (HPT axis). Briefly, the hypothalamus synthetizes and releases the thyrotropin-releasing hormone (TRH) into the pituitary portal circulation. TRH stimulates the release of thyrotropin (TSH) from the anterior pituitary, which in turn stimulates the synthesis and release of thyroid hormones, 3,5,3′,5′-tetraiodothyronine (T4) and 3,5,3′-triiodothyronine (T3) by the thyroid gland (8). T4 is exclusively secreted by the thyroid gland whereas nearly 80% of the circulating T3 results from peripheral conversion of T4 through the activity of the deiodinase enzymes located in target tissues, including the central nervous system (11). The action of the three different deiodinase enzymes deiodinase leads to either activation or inactivation of the thyroid hormones allowing a fine-tuning of thyroid hormone action at the tissue, cellular, and subcellular level by regulating the local availability of active thyroid hormone T3. The excess of thyroid hormone is commonly referred to as thyrotoxicosis/hyperthyroidism, and it promotes a hypermetabolic state characterized by increased resting energy expenditure, weight loss, increased lipolysis, and gluconeogenesis (11, 12). Conversely, a reduction in thyroid hormone levels, hypothyroidism, is associated with a hypo metabolic state characterized by reduced resting energy expenditure, weight gain, reduced lipolysis, and reduced gluconeogenesis (8). The issue of the pathways involved in the thyroid disrupting effect exerted by PFAS was recently reviewed (13). As stated by Ghassabian et al., any step in the biosynthesis and secretion of thyroid hormones could potentially be affected by PFAS exposure. Several mechanisms could be envisaged, including: i) impairment of iodine uptake by thyroid cells through a competitive mechanism and/or direct inhibition of the sodium/iodide symporter (NIS); ii) interference with thyroglobulin synthesis; iii) modification of Thyroperoxidase (TPO) activity; iv) interference with feedback mechanisms or with thyroid hormone biological effects through disruption of TH signaling pathway, deiodinase enzyme activity or TH binding proteins (13). Aim of this article is to review current data on the thyroid disrupting effect of PFAS, particularly focusing on the differences between long- and short-chain compounds, and on newly emerging PFAS. In vitro findings, data in exposed workers, and hazards for maternal-infant thyroid status will be reviewed.
Long-Chain PFAS: PFOA and PFOS
Concern on possible risks of PFAS for human health emerged when long-chain perfluoroalkyl carboxylic acids (PFCAs) and long-chain perfluoroalkane sulfonic acids (PFSAs) were shown to be ubiquitously present in the human body (14, 15). The long-chain PFAS include perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA). For many decades PFOA and PFOS were used to give surfactant properties to a variety of industrial products. There is compelling evidence for their persistence in the human body for long time. PFOS belongs to the PFSAs, whereas PFOA belongs to the PFCAs. Originally, the PFOA exposure was associated with thyroid dysfunctions and with kidney and testicular cancer, while PFOS exposure was mainly linked to decreased fertility and adverse developmental effects in fetus. Exposure to PFOA and PFOS was also correlated to an impaired immune response in children and to increased cholesterol levels and obesity in adults (7). Due to these hazardous effects, long-chain PFAS and their precursors were phased out by major manufacturers in Europe, Japan and U.S. thanks to the U.S. Environmental Protection Agency (EPA) 2010/15 PFOA Stewardship Program (16). Consequently, alternative compounds were synthetized, which mainly include short-chain fluorotelomer-based products. These short-chain compounds were considered to be safer for human health and for the environment.
Time trends from National Health and Nutrition Examination Survey (NHANES) showed reduced serum levels of PFOA and PFOS since the phase-out of these compound, indicating a reduced human exposures (2). On the other hand, long-chain PFAS continue to be produced by those companies which did not agree with stewardship commitments. Thus, despite reduced levels, PFAS were still detectable in 95% of NHANES subjects in 2013–2014 (17). Consistent serum levels for PFOS (35.3 ng/ml) and PFOA (5.6 ng/ml) were also found in pregnant women (18). More than 60% of U.S. children (aged 3–11 years) who were born after PFOS and PFOA were phased out still had detectable levels of 14 PFAS, including PFOS and PFOA (19). The European Food Safety Authority (EFSA) recently reassessed the risks of these substances for human health after a request of the European commission by performing a second evaluation taking into account data emerged after the first survey in 2008. The CONTAM group (EFSA’s Panel on Contaminants in the Food Chain) is assessing possible risks to human health from PFAS other than PFOS and PFOA (20). On July 4, 2020, restrictions carried out by the European Chemicals Agency (ECHA) on PFOA came into force following further scientific assessments.
Short-Chain and Emerging Replacement PFAS
With the phase-out of long-chain PFAS, companies shifted to short-chain fluorotelomer-based chemistry. These shorter PFAS are commonly known as C6 PFAS because they contain six fully fluorinated carbon groups with additional non-fluorinated carbons. By substituting long-chain PFAS with the short-chain ones, industry expected that the latter compounds might be both less toxic than the original PFAS and less persistent in the human body. However, data on the safety and bio-persistence of these shorter PFAS are still controversial (21, 22). Indeed short-chain PFASs seem to be persistent as their long-chain counterparts and show different, but not less worrisome effects on human health. Their widespread distribution in the environment is also a matter of concern (21, 23, 24). The main problem of these compounds is that they do not break down quickly after their intended use; consequently, they are not easily cleared up from the environment. In addition, the activated carbon filtration methodology, currently used to remove long-chain compounds from water, is less effective in removing the short-chain compounds (21). Short-chain PFAS may be divided in two main types: PFASs with carbon chain lengths of 5 and lower, and PFASs with carbon chain lengths of 7 and lower. Among these short-chain compounds, data on kinetics and toxicity in humans mainly regard perfluorohexanesulfonic acid (PFHxS). Its effects are similar to those of PFOS, making PFHxS a poor alternative. Although data regarding other short-chain PFAS are scanty, data from the literature support the hypothesis that they might be less toxic than PFOS and PFOA. Another short-chain PFAS, pentafluorobenzoic acid (PFBA) was found to be present at high concentrations in human tissues and especially in the brain. These data would imply that the short-chain PFAS might bio accumulate in humans at a higher degree than what expected from experiments in animals. Moving to environmental effects, it would seem that PFOS/PFOA and other long-chain PFAS are generally more toxic than the short-chain analogues even if the toxicity of short-chain PFAS is still not sufficiently investigated. However, some investigations indicate that at least the short-chain Fluorotelomer alcohols (FTOHs) may have higher endocrine disrupting effect than its analogue long-chain FTOHs (25).
Further alternatives to long-chain PFAS are represented by large fluoro-ether PFAS such as perfluoro-2-propoxypropanoic acid (GenX) and 4,8-dioxa-3H-perfluorononanoate (ADONA). These compounds were engineered with ether linkages and sites of hydrogenation in the effort to reduce their biological half-life (26). These PFAS replacements are produced in large quantities and recently, the public attention has shifted towards important levels of these PFAS compounds found from drinking water in North Carolina. One of these commercial mixtures was GenX, a DuPont’s substitute for PFOA. Data regarding the possible toxicity of these new emerging PFAS are scanty, but the few ones are not encouraging. Indeed, as shown in recent in vitro studies (27, 28), the toxicity of GenX was reported to be greater as compared with that of PFOA and PFOS. This is because GenX activates the Peroxisome-proliferator-activated receptor alpha (PPARα) pathway in mouse liver cell lines and causes cell injury (29). In animal models, GenX was also shown to be hepatotoxic and cancerogenic (28, 30–32). GenX is also highly mobile in the environment being detected faraway from its source. In consideration of the above reported data, GenX was marked as a Substance of Very High Concern (SVHC) by the ECHA in June 2019 (33). At difference with GenX, the exposure to another new generation PFAS named Perfluoro {acetic acid, 2-[(5-methoxy-1,3-dioxolan-4-yl)oxy]}, ammonium salt (C6O4) was recently demonstrated to not exert adverse effect on thyroid cells in vitro (34). Table 1 shows the most representative PFAS divided in three main groups as Long-Chain, Short-chain and Emerging PFAS.
Table 1 The most representative PFAS were divided in three main groups as Long Chain, Short-chain and Emerging PFAS showing each chemical structure.
To summarize our current knowledge, long-, short-chain, and emerging PFAS are potentially dangerous for human health making further studies and monitoring mandatory.
Endocrine Disruptive Effects of New and Old Generation PFAS on the Thyroid Gland
Endocrine-Disrupting chemicals (EDCs) are defined by the Endocrine Society as: “an exogenous [non-natural] chemical, or mixture of chemicals, that interferes with any aspect of hormone action.” Because of the endocrine system’s critical role in so many important biological and physiological functions, impairments in any component of the endocrine system can lead to disease (35, 36). Due to the thyroid gland and thyroid hormones important role in normal maintenance of metabolism and their critical role in fetal and childhood development, the disruption of thyroid function could cause several problems for the human health. Several studies recognized the ability of PFAS to interfere with hormone systems acting as EDCs (7, 35, 36). However, results were not consistently reported by all studies, being the discrepancy higher when a comparison among long-, short-, and new emerging PFAS were made. Nevertheless, PFAS potential interference with thyroid function was investigated taking into account different categories of subjects including exposed workers, general population, and pregnant women and infants. In addition, in vitro experiences might be also helpful for understanding the mechanisms of actions of these compounds.
In Vitro Experiences
Laboratory studies on thyroid cell cultures showed that in vitro exposure of thyroid cells to several PFAS can have various thyroid-disrupting effects. An accumulation of PFOS and PFOA was documented in thyroid cells, and a cytotoxic effect was observed after exposure to extremely high concentrations of these compounds (37). In addition, PFOS and PFOA reduce thyroperoxidase (TPO) activity in tumor thyroid cells lines (38) and PFOS was suggested to act as a thyroid hormone receptor (THR) agonist in GH3 cells as found by using THRα and THRβ-mediated luciferase reporter assay (39). Interestingly, Conti et al., showed that PFOS (but not PFOA) is able to inhibit the iodide accumulation in FRTL-5 cells mediated by NIS. The same finding was reported in non-thyroid cells with an eterologus NIS expression (40).
A recent in vitro study compared the potential thyroid disrupting effects of long-short-chain PFAS (PFOA and PFOS) and four different short-chain PFAS [including perfluorobutane sulfonic acid (PFBS), PFBA, perfluoroalkyl phosphonic acid (PFPA), and perfluoropentanoic acid (PFPeA)]. The results showed that short-chain PFAS had no cytotoxic effects on rat thyroid cells and did not interfere with thyroid-stimulating hormone (TSH)-dependent cyclic adenosine monophosphate (cAMP) production (41).
Regarding new emerging PFAS, a recent study by Coperchini et al., reported that FRTL-5 cells exposed to increasing concentrations of GenX displayed both genotoxic and cytotoxic effects (42).
Data on Animal Models
Evidences derived from animal models suggested that PFASs may alter thyroid hormone homeostasis (7), however, given the toxic kinetics and tissue distribution of PFASs that is known to be species-specific (2), extrapolating data from animals studies and compare them to humans does not allow to draw firm conclusions.
Previous data obtained in laboratories mainly found that PFAS reduce the circulating levels of thyroid hormones in diet-exposed animals, mainly by increasing their metabolic clearance rate (43). The thyroid disruptive effect of PFAS was investigated in recent studies. In particular, two main studies investigated the effect of PFOA and the new emerging PFAS, GenX, in mice and rats. Conley et al., characterized the potential maternal and post-natal toxicities of oral GenX in Sprague-Dawley rats during sexual differentiation and assayed circulating maternal thyroid hormones (44). They found that GenX caused a dose-responsive up-regulation of 28 different genes involved in the PPAR signaling pathway (influencing lipid catabolism, fatty acid uptake, and lipoprotein transport and assembly. The majority of shared, up-regulated genes were associated with fatty acid metabolism. A similar effect was found in pregnant mice livers. Maternal serum displayed dose-responsive decrease in all measured thyroid hormones, indeed total thyroxine (T4) levels were significantly lower than non-exposed pregnant mice, while serum total triiodothyronine (T3) levels were below assay detection levels (i.e., <0:2 ng=ml), at least for higher doses. These data are in line with previous studies in mice which found that PFOS and PFOA reduced both T3 and T4 in mother serum. The only difference between these studies was related to the fact that in the earlier ones T4 rather than T3 was reduced at a greater extent (44). Another study in mice is the one by Blake et al., who compared the toxicity of PFOA and GenX in pregnant mice. They reported that in mice exposed to PFOA or GenX, high levels of both compounds could be retrieved in the placenta. In addition they found an increase in placenta weight, an increase in placental lesions, and lower embryo-placenta weight ratios. A placental thyroid hormones disruption was specifically exerted by GenX (31).
Zebrafish represents another well established model for studying the effects of PFAS, and recent studies provided potentially interesting findings. Indeed, Zhang et al., recently reported increased whole-body thyroid hormones in zebrafish larvae [embryo collected at 0.5 to 2.0 h post fecondation (Hpf). Exposure ended 96 hpf)] exposed to 8:8 PFPiA, Perfluoroalkyl phosphinic acids (PFPiAs) a class of per- and PFAS along with perfluoroalkyl phosphonic acids (PFPAs). In details, after exposure to 0.5–50 nM of 8:8 PFPiA in zebrafish larvae, an increase of T4 and T3 was observed. In addition, corticotropin-releasing hormone (CRH) and TSHβ were down-regulated and uridinediphosphate-glucuronosyltransferase (UGT1AB) resulted up-regulated. The authors suggested that this should be regarded as a compensatory response to the hyperthyroid status (45). On the contrary, the recent study by Kim et al., showed an up-regulation of corticotropin releasing hormone b (CRHB), thyrotropin receptor (TSHR), and thyroid transcription factor-1 (NKX2.1) genes which was suggestive of a negative feedback in response to decreased circulating thyroid hormones (46). Finally, Rodriguez-Jorquera et al., performed a blood transcriptomic analysis in fish exposed to PFAS reporting an up-regulation, mainly promoted by PFOS, of thyroid hormone receptor beta (TR-β) (47). This increase expression was hypothesized to be involved in a non-correct thyroid hormones binding and consequent alteration of the hypothalamus-pituitary-thyroid axis function. This study highlighted that also small concentrations of organic contaminants may be detected in the bloodstream (47).
Another excellent model to test thyroid axis disruption is Xenopus laevis; indeed, thyroid hormones are highly conserved across vertebrates (48). In a recent study, Fini et al., investigated the potential consequences of human amniotic fluid exposure to some chemical contaminants during embryonic development on thyroid hormone signaling (49). Exposure to a mixture of chemicals including PFOA and PFOS at those concentrations found in human amniotic fluid affected thyroid hormone-dependent transcription, gene expression, brain development, and behavior in early embryogenesis. In particular a dose-dependent effect of short-term (72 h) exposure to PFOA and PFOS alone was observed. These results suggested a potential adverse effect of PFAS exposure and fetal development (49).
The potential adverse role of PFAS for thyroid function was also investigated in cats. In particular, the interesting study by Wang et al., compared the ΣPFAS levels in the serum of Northern California cats and humans collected during two time periods: 2008 to 2010 and 2012 to 2013 (50). The ΣPFAS was composed of: PFOS, PFOA, perfluorohexane sulfonate (PFHxS), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDeA), perfluoroundecanoic acid (PFUnDA), N-methyl-perfluorooctane sulfonamidoacetic acid (MeFOSAA) had detection frequencies, Perfluorooctanesulfonamide (FOSA) and N-ethyl-perfluorooctane sulfonamidoaceticacid (EtFOSAA). The results showed that circulating concentrations of long-chain perfluorinated carboxylic acids, especially PFNA and PFUnDA, were significantly higher in cat than in humans. Furthermore, serum from hyperthyroid cats in the second time period showed higher ΣPFAS level (9.50 ng/ml) compared to non-hyperthyroid cats (7.24 ng/ml). In particular, serum PFOS levels were significantly higher in the hyperthyroid cats. This result may indicate a possible link between PFAS levels and hyperthyroidism in cats (50). Moving on data on great mammalians, Routti et al., examined the correlation between levels of PFAS and thyroid hormones and genes transcripts in in adult male Atlantic walruses (n ¼ 38) from Svalbard (Norway). They found that transcript levels of nuclear receptor subfamily 3 group C member 1 (NR3C1), the thyroid hormone receptor alpha (THRα) and the retinoic X receptor alpha (RXRα) were negatively correlated with plasma ΣPFAS concentrations. However, these results should be interpreted with care since statistical significance was reached only when three outliers were excluded (51). Very limited data are available regarding the possible effect of chronic exposure to PFAS on thyroid morphology, coming from experimental animal models. Indeed, it was demonstrated by using a zebrafish model that chronic exposure to PFOS would alter the normal structure of thyroid follicular cells (52). Chen et al. reported a significant reduction of the nuclear area of thyroid follicular epithelial cells of fishes chronically exposed to PFOS. Moreover, mitochondria and endoplasmic reticulum of zebrafish chronically exposed to PFOS were significant altered as evidenced by Transmission electron microscopy analysis showing structural modifications in intracellular organuli, such as ribosomes, mitochondria, and endoplasmic reticulum. At the tissue level, chronic PFOS exposure also caused oedema of the interstitial tissue. These morphological changes in the structure of thyroid gland were accompanied by disturbances in thyroid function, as assessed by a decline in circulating thyroid hormone concentrations in this animal model (53).
On the other hand, a study performed on dams exposed to PFHxS reported no statistically significant effects on thyroid gland weights and histopathology (54).
Taken together the above reported laboratory evidences highlight the adverse effects of the new emerging PFAS on thyroid hormones and thyroid-related-genes suggesting that they could also be more dangerous than their predecessors long-chain PFAS.
Interference of PFAS on Thyroid Function: New Data Collected From Exposed Workers, General Population, and From Patients With Underlying Thyroid Diseases
Studies performed before 2017 regarding the interference of PFAS with thyroid function in humans, mainly highlighted a higher occurrence of hypothyroidism due to the exposure to PFOA (and even if with fewer evidences to PFOS) both in the general population and in the exposed communities (7). In 2018, a study performed in Korean adult general population, found that the 10-year trend of circulating levels of 13 PFAS gradually increased from 2006 to 2013 and subsequently decreased over the following years. In particular, it was found a significant correlation between free thyroxine (FT4) levels and PFNA, PFHxS, and PFDA, moreover significant differences were observed between participants with and without diabetes as to the levels of PFHxS and PFDoDA. In particular, some gender-related specificities were found. Indeed, while in male patients, PFNA, PFOS, PFDA, and PFDS showed the strongest positive correlation with serum FT4 levels, in females FT4 levels were more strongly related to PFBS, PFHxA, PFHxS, PFNA, PFOS, PFDA, and PFUnDA (20). Taken together, positive associations between FT4 and PFOS, PFNA, PFHxS, PFDA, and PFOA levels were registered pointing out a stronger correlation of PFOS with thyroid hormone levels than PFOA, confirming results of previous studies (55–57). Finally, in both male and female participants, TSH showed no significant correlations with PFAS serum levels. The positive correlation observed within PFAS and thyroid hormone levels was attributed to the interference of these compounds with the binding of FT4 carrier proteins which ultimately would disrupt thyroid hormone homeostasis and affect basal metabolic rate and protein synthesis (58). Another study longitudinally evaluated the PFAS circulating levels within and between individuals over nearly two decades as well as their relationship to thyroid hormones levels recruiting in this case participants who lived or worked within a 5-mile radius of a Feed Materials Production Center collected as early as 1991 in the Fernald Community Cohort (59). The study investigated the relationship between changes in PFAS serum levels and repeated measures of total T4 and TSH, reporting significant positive associations between PFOS and an increase in circulating TSH levels. On the other hand, no associations between PFAS and total T4 or TSH were detected by using crude models of latent effects. In the adjusted latent model, a positive association between serum PFNA and total T4 was found. Finally, by using the adjusted latent model [which included covariates for age, year of measurement, sex, education, income, marital status, and body mass index (BMI)] an increase in total T4 was related to serum PFNA levels, with no relationship with TSH (59). A meta-analysis performed by Kim et al. (which considered all studies from 1985 to 30 April 2017 regarding serum levels of PFOA, PFOS, and PFHxS) reported that blood PFOS concentrations were positively correlated with free T4 and negatively correlated with total T4 and total T3. PFOA concentrations were negatively correlated with total T4 while PFHxS showed a negative correlation with total T4, finally suggesting that PFASs would negatively associate with total T4 (60). In a study evaluating the associations between serum PFAS concentrations and circulating thyroid hormones in a population of Alaska natives it was suggested that the effects of PFAS exposure on thyroid hormone homeostasis may differ between sexes. Indeed, PFOS and PFNA were positively associated with circulating free triiodothyronine (FT3) in females and negatively associated with FT3 in males participants (61).
In a general population study with long-term high exposure to PFHxS, PFOS, and to a lesser extent PFOA through drinking water constituted by an open (dynamic) cohort, defined as people who have lived in Ronneby municipality at any time during the time period 1980–2013, no increase in the risk of clinically detected hyperthyroidism was observed, neither in men nor in women (62).
Prenatal Exposure to PFAS: Effects on Maternal and Neonatal Thyroid Function
Neonatal and maternal thyroid function are critical for children growth and neurodevelopment. Indeed, during early pregnancy, the fetus is dependent on maternal thyroid hormones until thyroid hormone fetal production increases around 18–20 weeks of gestation (63). Also after birth a normal thyroid function is required for a regular neurodevelopment and growth (64). Alterations in maternal thyroid function during pregnancy are associated with several adverse fetal outcomes, such as neurodevelopmental deficits, preterm delivery, and reduced fetal growth (65). Additionally, neonatal thyroid dysfunction has been associated with impaired neurodevelopment (66–68). Many epidemiological studies investigated the relationship between exposure to PFAS during the prenatal period and alterations in maternal and neonatal thyroid function. In particular, many studies published prior to the dismissing of PFOA and PFOS indicated that exposure to several long-chain PFAS could influence TSH and thyroid hormone levels both in mothers and newborns. Although results were not completely consistent, an overall association between higher PFAS serum/plasma levels and a reduction in T4 levels and/or an increase in TSH levels was described (69), especially for PFOS. The effect on circulating TSH and thyroid hormones was generally small and likely of limited clinical significance, even if available evidences suggested that women with autoimmune thyroiditis might be at higher risk for developing subclinical hypothyroidism during pregnancy if exposed to PFAS (7).
Several clinical studies have been published in the last three years regarding the possible relationship between PFAS exposure and thyroid dysfunction during pregnancy. These studies are particularly relevant since they belong to the post-out of production era of long-chain PFAS, even if, due to their long half-life, persistency, and bioaccumulation these compounds can still be found in patient’s sera, although at lower concentrations. In the last years important data derived from several prospective large series maternal cohorts. The results of these studies are summarized in Table 2. A specific focus on fetal outcomes of PFAS exposure and the possible role of « mixture » exposure to multiple PFAS emerged. Moreover, the possible role of thyroid autoimmunity in the mother and also the role of fetal sex were both considered as modifying factors.
Table 2 Summary regarding recent data from several prospective large series maternal cohorts.
Some of these studies focused directly on the effect of several PFAS on maternal thyroid function. For example, Inoue et al. (72) evaluated the gestational-week specific associations between maternal TSH and FT4 levels and the plasma concentrations of six different long-chain PFAS [PFOS, PFOA, PFHxS, perfluoroheptanesulfonic acid (PFHpS), PFNA, and PFDA] during the first and the second trimester of pregnancy. Samples were taken from a national Danish cohort of pregnant women enrolled between 1996 and 2002. The results showed that, even though in all women, the typical U-shaped trend of TSH levels modification was observed during the first two trimesters of pregnancy, higher levels of exposure to PFAS (in particular to PFOS, PFOA, PFHxS, and PFHpS) were associated with higher TSH levels when compared with women at lower levels of exposure. This significant difference could not be observed after the 10th week of gestation. The authors concluded that some gestational-week–specific association between high levels of exposure to several PFAS and TSH levels in early gestation could exist.
Another study aimed at evaluating the relationship between PFAS and maternal thyroid function parameters was the one by Aiumzi et al. (74) who performed a large prospective study on a cohort of 1,885 pregnant women included in the Shanghai Birth Cohort. In details, 10 different long-chain PFAS [including PFBS, PFOA, PFHpA, PFOS, PFHxS, PFNA, PFUNDA, PFDA, PFDoA, and Perfluorooctanesulfonamide (PFOSA)] were measured in maternal blood collected before the 16th gestational week and their levels were related with those of maternal TSH, FT3, FT4, and TPOAb. The results showed that PFOA and PFHxS were positively associated with FT4, while PFNA and PFHxS were positively associated with FT3. PFHxS was also negatively associated with TSH levels. The authors also separately analyzed results in TPO Ab positive and negative women. Among AbTPO negative women only a weak positive correlation between PFHxS and FT3 levels and an inverse U shaped relationship between PFHxS and FT4 was observed. In contrast, when only the TPO Ab positive women were taken into account, a significant direct correlation between PFNA and FT4 and significant, U-shaped, correlations between PFUNDA, PFOS, PFNA, and PFHxS with TSH levels was observed. These interactions appeared to be stronger in AbTPO women, as testified by higher beta values.
A very recent longitudinal study by Reardon et al. (77) extended the evaluation of a possible relationship between thyroid hormones and maternal thyroid function also to the postpartum period. The participants of a prospective Canadian birth cohort (the APrON Study), were enrolled, and data regarding FT3, FT4, TSH, and TPOAb maternal plasma levels were collected in each trimester and 3-months postpartum. The authors related thyroid function parameters and antibody levels to those of eight different PFAS (PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoA PFHxS, and PFOS) as well as with the levels of six different isomers of PFOS. The results showed that PFHxS levels as well as the total branched isomers of PFOS were positively associated with TSH in mixed-effect models, with strongest associations in the early phase of gestation. Throughout pregnancy and post-partum, PFHxS levels were inversely associated with FT4 levels and directly associated with TSH levels. When only TPOAb-positive women were taken into account, negative associations were found between PFUnDA levels and FT4 and between PFOS and TSH. These data would support the notion that the presence of thyroid autoimmunity can influence the effect of PFAS on thyroid homeostasis throughout pregnancy and post-partum.
Although several data regarding the effects of PFAS on thyroid homeostasis in pregnancy are available from previous studies, more recent papers have added new information on this topic. Some studies have evaluated if maternal PFAS exposure could alter thyroid function parameters in the newborns.
Preston et al. (70) investigated the association between PFAS exposure during early pregnancy and maternal and fetal thyroid function in a prospective cohort study in Boston, Massachusetts. In detail, the plasma concentrations of six long-chain PFAS (PFOA, PFOS, PFNA, PFHxS, EtFOSAA, and MeFOSAA) were evaluated in early pregnancy (median 9.6 weeks of gestation). Thyroid function parameters were measured in the same plasma samples and included TSH, total T4, T3 resin uptake (an indirect measure of thyroid hormone binding protein saturation by thyroxine), free T4 index (calculated as total T4 × T3 Uptake) (FTI), and TPO Ab. Neonatal total T4 was obtained by whole blood on filter paper from heel sticks.
The results showed that, although PFAS concentrations were not associated with maternal T4, PFOA, PFHxS, and MeFOSAA concentrations were inversely associated with maternal free T4 index. PFOA, PFOS, and PFNA concentrations were inversely associated with TSH levels only in TPOAb positive women. Prenatal PFOS, PFOA, and PFHxS maternal concentrations were inversely associated with T4 levels only in male, but not in female neonates. The authors suggested that these results support a role for PFAS exposure in influencing thyroid function in both mothers and infants.
A more recent work by the same group (71) evaluated the association of exposure to a combination of the same PFAS, instead of the single ones, on maternal and fetal thyroid function. The results showed that higher concentrations of the PFAS mixture were associated with significantly lower maternal free T4 index, with PFOA, MeFOSAA, EtFOSAA, and PFHxS contributing most to the overall effect of the mixture. In infants, higher concentrations of the PFAS mixture were associated with lower T4 levels, especially in males, with PFHxS and MeFOSAA giving the highest contribution to this effect. The authors concluded that there may be combined effects of prenatal exposure to multiple PFAS on maternal and neonatal thyroid function, but the direction and magnitude of these effects may vary across individual PFAS.
Itoh et al. (75) evaluated the correlation between prenatal exposure to eleven different PFASs [PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, perfluorotridecanoic acid (PFTrDA), and PFTeDA] and the levels of thyroid function parameters and thyroid autoantibodies [Ab thyroglobulin (Tg) and AbTPO] both in maternal and in cord blood. A multivariate linear model was constructed entering age at delivery, parity, pre-pregnancy BMI, educational level, alcohol consumption, and smoking habit during pregnancy as covariates. The main outcome was that both the newborn sex and the presence or absence of thyroid autoantibody in the mother could modify the relationship between maternal PFAS exposure and thyroid function.
Indeed, in thyroid-antibody negative women, maternal FT3 levels were positively associated with PFHxS, while in thyroid-antibody positive women PFNA plasma levels were positively related with FT3 levels. PFOA levels exhibited instead a significant inverse association with maternal TPOAb titer. No significant association between any PFAS and FT4 or TSH levels were observed independently from thyroid Abs status.
Next, the authors investigated the relationship between maternal PFAS exposure and the newborn thyroid function and thyroid autoantibody levels, in relation to the sex of the newborn. In male newborns, maternal PFOS levels were directly related with the TSH levels of the newborn in children from thyroid-antibody negative mothers but not in those from thyroid-antibody positive mothers. Always in male newborns from TA-negative mothers, PFDA and PFUnDA were inversely associated with the newborn FT3 levels.
At difference, in male newborns from TA-positive women, maternal PFDA was inversely associated with circulating TSH levels of the children.
On the other hand, in female newborn from TA-negative mothers, PFDoDA maternal levels were directly related with the girls TSH levels and PFDA and PFTrDA levels were positively related with the girls FT3 levels. Instead, in girls from TA positive mothers, an inverse relationship between PFDoDA maternal levels and the girls FT4 levels was observed. Lastly, a possible relationship between PFAS maternal levels and thyroid autoantibody levels in the offspring was sought. A direct relationship between PFOA, PFNA, and PFDA levels and TgAb levels was observed in girls born from TA positive women. The authors concluded that the relationship between different PFAS exposure and thyroid function perturbation in mothers and newborn is a complex phenomenon, likely influenced by both maternal autoimmunity and fetal sex.
The sex-based differences in the thyroid disrupting effects of PFAS exposure during pregnancy is intriguing, but the underlying mechanisms are still far from being elucidated. At present two main hypothesis were formulated. Itoh et al., suggested that differences in the elimination kinetics of PFAS between males and females, as previously shown for PFOA and PFOS in animal and in human studies may account for the different effects (80, 81), while other authors suggested that estrogen-induced increase in Thyroxine-binding globulin (TBG) production could alter measurements of circulating thyroid function parameters in newborn girls (82). The potential effect of maternal autoimmunity was also addressed by Lebeaux et al. (76) in a study examining data coming from a prospective cohort, the Health Outcomes and Measures of the Environment (HOME) Study, in which 468 pregnant women and their children coming from the Cincinnati area in US were enrolled. In particular the authors assessed the possible associations between TSH, FT3, FT4, TT4, and TT3 in maternal and cord blood and levels of four different PFAS (PFOA, PFOS, PFNA, and PFHxS) in the same samples. Two mixture modeling approaches [Bayesian kernel machine regression (BKMR) and quantile g-computation] and a multivariate linear regression were employed. The results showed that the levels of most of the analyzed PFAS were not associated with any thyroid function parameter, neither when considered alone nor as mixtures. When only women with positive thyroid autoantibodies were taken into account, a significant, even if slight, association between PFOS, PFOA, and PFHxS levels and fetal FT4 could be evidenced.
Only few studies evaluated whether the possible effect of PFAS on thyroid function could, in the end, result in clinically evident events, such as pregnancy complications or alterations in pregnancy development.
A very recent paper from the same Danish group of the study by Preston et al. (73). describes the results of a nested case-control study performed on the same aforementioned national cohort of pregnant women. In this case, the plasma levels of the six PFAS were compared between a group of 220 women who experienced miscarriage during weeks 12–22 of gestation and a group of 218 women with pregnancies resulting in live births. Data were adjusted for maternal age, parity, socio-occupational status, smoking, alcohol intake, and maternal history of miscarriage. The authors observed an increase in odds for miscarriage associated with increasing PFOA and PFHpS levels. In particular, the odd ratios (ORs) for having a miscarriage comparing the highest PFOA or PFHpS quartile to the lowest were 2.2 and 1.8, respectively. The ORs were also elevated for the second or third quartile of PFHxS or PFOS, but no consistent exposure-outcome pattern emerged. This association was stronger in parous women, while findings were inconsistent among nulliparous women.
Another very recent paper by Xiao et al. (78). studied a population-based prospective cohort of 172 mother-singleton pairs from the Faroe Islands, a population known to consume high quantities of whale meat, which implies elevated PFAS intake. In detail, the maternal serum levels of nine different PFAS (PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFHxS, PFHpS, PFOS) as well as three different PFAS precursors (NEtFOSAA, NMeFOSAA, and FOSA) were obtained at 34 weeks of gestation. In parallel, thyroid function parameters were evaluated in both cord and maternal serum. The results showed an inverse correlation between neonatal outcomes and PFAS levels. In particular, a doubling of PFHxS and PFOS levels was associated with significant reduction in birth weight, birth length, and head circumference. A less relevant effect was also observed for other PFAS: an inverse associations between PFNA, PFDA, and PFOA with birth weight and between PFDA and PFHpS with birth length was found, with similar effects in boys and girls. Higher PFNA, PFOS, PFDA, and PFOA maternal levels were associated with an increase in maternal TSH levels. When the correlation between maternal PFAS levels and maternal thyroid hormones was evaluated, an interesting sexual dimorphism was found. Indeed, in mothers bearing female fetuses, PFOS and PFOA levels were positively associated with maternal T4 and FTI levels, while there was a negative association for mothers bearing male fetuses. The analysis of the possible correlations between PFAS and cord blood thyroid function parameters consistently showed a direct association between PFAS levels and cord TSH, in particular for PFOS, PFOA, PFDA, PFNA, and FOSA. Finally, the authors evaluated if the effect of PFAS on birth outcomes was mediated by modifications of maternal thyroid function, but the analysis of mediated effects supported a direct role of PFAS on fetal outcomes not mediated by alteration in thyroid function parameters.
One of the main problems in addressing the issue of thyroid disrupting effects consequent to PFAS exposure during pregnancy, is that some evidences suggested a direct detrimental effects of PFAS on the child neurological development, independently from their effects on thyroid function.
Indeed, a positive association between PFAS exposure and several neurological traits such as impulsivity (83), attention-deficit/hyperactivity disorder (ADHD) (84, 85), behavioral problems (86), or poorer executive function (87) was reported by some epidemiological studies. However, these findings were in most cases not confirmed by longitudinal studies, reporting no association between ADHD (88, 89), autism spectrum disorders (88, 90, 91), parent- or teacher-reported behavioral scores (86, 92, 93), or cognitive abilities (94, 95) of exposed children. Some studies showed only weak to moderate associations between child’s behavior and prenatal PFOA, PFNA, and PFDA exposure (96). A recent investigation of nine European cohorts with a total of 4,826 mother-child pairs found overall no associations between prenatal and early postnatal (up to 24 months of age) PFOS and PFOA exposure and ADHD risk (97). Up to now, only a very recent study by Luo et al. addressed the issue of the role of thyroid hormone perturbations as the mechanism through which PFAS would impair neurodevelopment in children (79). In details, Luo et al., evaluated the association between maternal prenatal exposure to six six different PFAS (PFOS, PFOA, PFHxS, PFHpS, PFNA, and PFDA) and behavioral outcomes at 7 and 11 years of age in a cohort of 758 mother-child pairs taken from the Danish National Birth Cohort between 1996 and 2002. Statistical models were adjusted for maternal age, parity, socioeconomic status, pre-pregnancy BMI, gestational week of blood collection, smoking and alcohol intake during the 1st trimester and parent’s behavioral scores. The Authors found a significant association between PFOS, PFOA, PFNA, and PFHxS levels with behavioral difficulties at 7 years of age, but only PFNA levels were associated to behavioral difficulties also at 11 years of age, both in parents- and children-reported measures (79).
The mediation analysis showed that 10–20% of the effect of PFOS, PFOA, PFNA, and PFHxS on the child behavior outcome at 7 years was probably mediated by maternal thyroid hormone alterations, while no mediating effects were observed for any outcome measures at 11 years. The authors concluded that prenatal PFNA exposure was associated with behavioral difficulties in childhood at 7 and 11 years, possibly mediated by maternal thyroid hormones. However, the Authors concluded that the potential slight mediating effects of maternal thyroid hormones in early gestation should be further investigated (79).
Conclusions
PFAS (both long and short chain and their alternatives) are widespread environmental pollutants. The potential hazards of exposure to these compounds are raising concerns in the scientific community. Among their many detrimental effects, these compounds may act as endocrine disruptors and, at least some of them, are also considered as thyroid disruptors. Although the role of PFAS as thyroid function disrupters is still controversial, in vitro studies seem to be in overall agreement regarding the harmful effects of PFAS on thyroid cells. Indeed, PFAS harmful effects on thyroid cells would include accumulation, cytotoxicity, genotoxicity, interference with TH synthesis, TPO function, and iodine uptake, as reported by several by in vitro studies. Furthermore, studies performed in animal models confirmed a thyroid disrupting effect of exposure to both new and old generation PFAS. Indeed, PFAS dietary ingestion, induces changes in circulating levels of thyroid hormones, mainly by increasing their metabolic clearance rate. An interesting and worrisome finding is that PFAS accumulate in the placentas of pregnant mice, where they could modify thyroid hormone levels, potentially affecting the development of the fetus; in addition data on zebrafish highlighted an interference of PFAS on embryogenesis. Thus, based on in vitro results and on animal models it could be suggested that PFAS exert a thyroid disrupting effect. On the other hand, in vivo data in humans are by far more controversial as to the potential thyroid disrupting effect of PFAS with great discrepancy among different studies. At present, the onset of hypothyroidism in PFAS exposed communities as well as in the general population, would represent the most frequent thyroidal effect of the exposure to PFAS, but again with some inconsistencies. Furthermore, PFAS exposure during pregnancy seems to cause slight but statistically significant alterations in thyroid function parameters, both in mothers and in newborns. Still a lot remains to be elucidated regarding the clinical relevance of this phenomenon. Indeed, even if it is probable that PFAS exposure can cause detrimental effects on fetal growth, it is still not clear if this effect is mediated by alterations in thyroid hormone homeostasis. Moreover, long-term studies evaluating the possible neurological consequences of PFAS-related thyroid dysfunction during pregnancy will be needed. Figure 1 summarizes the available evidence regarding PFAS potential thyroid disrupting effects in different experimental settings (in vitro data, animal models, general population, and pregnant women).
Figure 1 Effect of PFAS on thyroid function in: animal models (upper left), in vitro models (lower left), human population (upper right), pregnant women (lower right).
Conclusive Remarks
In conclusion, based on the present review of the literature, we would suggest that available evidence mainly provide by in vitro studies and in animal models, would support a thyroid-disrupting effect of the exposure to both old- and new-generation PFAS. However, studies in humans provided contrasting results suggesting the need for more longitudinal, long-term-exposed population studies, specifically designed for evaluating the biological consequences of chronic exposure to PFAS. A further aspect to be addressed will be to evaluate whether exposure to a combination of multiple PFAS could have stronger effects as compared to the exposure to a single PFAS.
Author Contributions
FC: Conceptualization, Writing, Original draft preparation. LCr: Writing, Original draft preparation. GR: Writing, Table preparation. FM: Reviewing and Editing. MR: Reviewing and Editing, Supervision. MI: Writing, reviewing and editing. LCh: Supervision. All authors contributed to the article and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Abbreviations
PFAS, Per- and polyfluoroalkyl substances; ITRC, Interstate Technology & Regulatory Council; HTP axis, hypothalamic–pituitary–thyroid axis; TRH, thyrotropin-releasing hormone; PFCAs, Perfluoroalkyl carboxylic acids; PFSAs , Perfluoroalkane sulfonic acids; PFOS, Perfluorooctane sulfonic acid; PFOA, Perfluorooctanoic acid; EPA, Environmental Protection Agency; NHANES, National Health and Nutrition Examination Survey; EFSA, European Food Safety Authority; CONTAM, EFSA’s Panel on Contaminants in the Food Chain; ECHA , European Chemicals Agency; PFHxS, Perfluorohexanesulfonic acid; PFBA, Pentafluorobenzoic acid; FTOHs , Fluorotelomer alcohols; GenX; C6O4 , Perfluoro-2-propoxypropanoic acid; Perfluoro{acetic acid, 2-[(5-methoxy-1,3-dioxolan-4-yl)oxy]}; ADONA, 4,8-dioxa-3H-perfluorononanoate; PPARα, Peroxisome-proliferator-activated receptor alpha; SVHC, Substance of Very High Concern; EDCs, Endocrine-Disrupting chemicals; TPO , Thyroperoxidase; TH , Thyroid hormone; THR, Thyroid hormone receptor; PFBS, Perfluorobutane sulfonic acid; PFPA, Perfluoroalkyl phosphonic acids; PFPeA, Perfluoropentanoic acid; TSH, Thyroid-stimulating hormone; cAMP , Cyclic adenosine monophosphate; T4 , Thyroxine; T3, Triiodothyronine; Hpf, Hours post fecondation; PFPiAs, Perfluoroalkyl phosphinic acids; CRH, Corticotropin-releasing hormone; UGT1AB, Uridinediphosphate-glucuronosyltransferase; CRHB, Corticotropin releasing hormone b; TSHR , Thyrotropin receptor; NKX2.1, Thyroid transcription factor-1; TR-β, Thyroid hormone receptor beta; PFNA, Perfluorononanoic acid; PFDA, Perfluorodecanoic acid; PFUnDA, Perfluoroundecanoic acid; MeFOSAA, N-methyl-perfluorooctane sulfonamidoacetic acid; FOSA, Perfluorooctanesulfonamide; EtFOSAA, N-ethyl-perfluorooctane sulfonamidoaceticacid; NR3C1, Nuclear Receptor Subfamily 3 Group C Member 1; THRα, Thyroid hormone receptor alpha; RXRα , Retinoic X receptor alpha; FT4, Free thyroxine; TBG, Thyroxine-binding globulin; PFDoDA, Perfluorododecanoic acid; PFDS , Perfluorodecane sulfonic acid; PFHxA, Perfluorohexanoic acid; BMI, Body mass index; FT3, Free triiodothyronine; PFHpS, Perfluoroheptanesulfonic acid; PFOSA, Perfluorooctanesulfonamide; Ab , Antibody; PFTrDA , Perfluorotridecanoic acid; Tg, Thyroglobulin; HOME; ADHD, Health Outcomes and Measures of the Environment; Attention-deficit/hyperactivity disorder; BKMR, Bayesian kernel machine regression; ORs, Odd ratios; FTI, Free T4 index; NIS , Sodium/iodide symporter.
Glossary
References
1. Prevedouros K, Cousins IT, Buck RC, Korzeniowski SH. Sources, fate and transport of perfluorocarboxylates. Environ Sci Technol (2006) 40(1):32–44. doi: 10.1021/es0512475
2. Jian JM, Chen D, Han FJ, Guo Y, Zeng L, Lu X, et al. A short review on human exposure to and tissue distribution of per- and polyfluoroalkyl substances (PFASs). Sci Total Environ (2018) 636:1058–69. doi: 10.1016/j.scitotenv.2018.04.380
3. Buck RC, Franklin J, Berger U, Conder JM, Cousins IT, de Voogt P, et al. Perfluoroalkyl and polyfluoroalkyl substances in the environment: terminology, classification, and origins. Integr Environ Assess Manage (2011) 7(4):513–41. doi: 10.1002/ieam.258
4. Bowman JS. Fluorotechnology is critical to modern life: the FluoroCouncil counterpoint to the Madrid Statement. Environ Health Perspect (2015) 123(5):A112–3. doi: 10.1289/ehp.1509910
5. Stubleski J, Salihovic S, Lind L, Lind PM, van Bavel B, Kärrman A. Changes in serum levels of perfluoroalkyl substances during a 10-year follow-up period in a large population-based cohort. Environ Int (2016) 95:86–92. doi: 10.1016/j.envint.2016.08.002
6. Hong S, Khim JS, Park J, Kim M, Kim WK, Jung J, et al. In situ fate and partitioning of waterborne perfluoroalkyl acids (PFAAs) in the Youngsan and Nakdong River Estuaries of South Korea. Sci Total Environ (2013) 445-446:136–45. doi: 10.1016/j.scitotenv.2012.12.040
7. Coperchini F, Awwad O, Rotondi M, Santini F, Imbriani M, Chiovato L. Thyroid disruption by perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA). J Endocrinol Invest (2017) 40(2):105–21. doi: 10.1007/s40618-016-0572-z
8. Brent GA. Mechanisms of thyroid hormone action. J Clin Invest (2012) 122(9):3035–43. doi: 10.1172/JCI60047
9. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev (2010) 31(2):139–70. doi: 10.1210/er.2009-0007
10. Oetting A, Yen PM. New insights into thyroid hormone action. Best Pract Res Clin Endocrinol Metab (2007) 21(2):193–208. doi: 10.1016/j.beem.2007.04.004
11. Brent GA. Clinical practice. Graves’ disease. N Engl J Med (2008) 358(24):2594–605. doi: 10.1056/NEJMcp0801880
12. Motomura K, Brent GA. Mechanisms of thyroid hormone action. Implications for the clinical manifestation of thyrotoxicosis. Endocrinol Metab Clin North Am (1998) 27(1):1–23. doi: 10.1016/S0889-8529(05)70294-2
13. Ghassabian A, Trasande L. Disruption in Thyroid Signaling Pathway: A Mechanism for the Effect of Endocrine-Disrupting Chemicals on Child Neurodevelopment. Front Endocrinol (Lausanne) (2018) 9:204. doi: 10.3389/fendo.2018.00204
14. Houde M, Martin JW, Letcher RJ, Solomon KR, Muir DC. Biological monitoring of polyfluoroalkyl substances: A review. Environ Sci Technol (2006) 40(11):3463–73. doi: 10.1021/es052580b
15. Giesy JP, Kannan K. Global distribution of perfluorooctane sulfonate in wildlife. Environ Sci Technol (2001) 35(7):1339–42. doi: 10.1021/es001834k
16. US Environment Protection Agency (EPA). Supporting Documents for Drinking Water Health Advisories for PFOA and PFOS. EPA 800-F-16-003. (2016). Available at: https://www.epa.gov/ground-water-and-drinking-water/supporting-documents-drinking-water-health-advisories-pfoa-and-pfos.
17. Centers for Disease Control and Prevention. Fourth Report on Human Exposure to Environmental Chemicals, Updated Tables. (2019).
18. Fei C, McLaughlin JK, Tarone RE, Olsen J. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Environ Health Perspect (2007) 115(11):1677–82. doi: 10.1289/ehp.10506
19. Ye X, Kato K, Wong LY, Jia T, Kalathil A, Latremouille J, et al. Per- and polyfluoroalkyl substances in sera from children 3 to 11 years of age participating in the National Health and Nutrition Examination Survey 2013-2014. Int J Hyg Environ Health (2018) 221(1):9–16. doi: 10.1016/j.ijheh.2017.09.011
20. EFSA CONTAM Panel. Risk to human health related to the presence of perfluoroalkyl substances in food. Efsa J (2020) 8(9):6223. doi: 10.2903/j.efsa.2020.6223
21. Brendel S, Fetter É, Staude C, Vierke L, Biegel-Engler A. Short-chain perfluoroalkyl acids: environmental concerns and a regulatory strategy under REACH. Environ Sci Eur (2018) 30(1):9. doi: 10.1186/s12302-018-0134-4
22. Wang Z, Cousins IT, Scheringer M, Buck RC, Hungerbühler K. Global emission inventories for C4-C14 perfluoroalkyl carboxylic acid (PFCA) homologues from 1951 to 2030, Part I: production and emissions from quantifiable sources. Environ Int (2014) 70:62–75. doi: 10.1016/j.envint.2014.04.013
23. Schwanz TG, Llorca M, Farré M, Barceló D. Perfluoroalkyl substances assessment in drinking waters from Brazil, France and Spain. Sci Total Environ (2016) 539:143–52. doi: 10.1016/j.scitotenv.2015.08.034
24. Shafique U, Schulze S, Slawik C, Böhme A, Paschke A, Schüürmann G. Perfluoroalkyl acids in aqueous samples from Germany and Kenya. Environ Sci Pollut Res Int (2017) 24(12):11031–43. doi: 10.1007/s11356-016-7076-4
25. Jensen AA, Warming A. Short-chain Polyfluoroalkyl Substances (PFAS). The Danish Environmental Protection Agency (2015).
26. Fromme H, Wöckner M, Roscher E, Völkel W. ADONA and perfluoroalkylated substances in plasma samples of German blood donors living in South Germany. Int J Hyg Environ Health (2017) 220(2 Pt B):455–60. doi: 10.1016/j.ijheh.2016.12.014
27. Gebbink WA, van Asseldonk L, van Leeuwen SPJ. Presence of Emerging Per- and Polyfluoroalkyl Substances (PFASs) in River and Drinking Water near a Fluorochemical Production Plant in the Netherlands. Environ Sci Technol (2017) 51(19):11057–65. doi: 10.1021/acs.est.7b02488
28. Gomis MI, Vestergren R, Borg D, Cousins IT. Comparing the toxic potency in vivo of long-chain perfluoroalkyl acids and fluorinated alternatives. Environ Int (2018) 113:1–9. doi: 10.1016/j.envint.2018.01.011
29. Sun S, Guo H, Wang J, Dai J. Hepatotoxicity of perfluorooctanoic acid and two emerging alternatives based on a 3D spheroid model. Environ Pollut (2019) 246:955–62. doi: 10.1016/j.envpol.2018.12.065
30. Sheng N, Cui R, Wang J, Guo Y, Dai J. Cytotoxicity of novel fluorinated alternatives to long-chain perfluoroalkyl substances to human liver cell line and their binding capacity to human liver fatty acid binding protein. Arch Toxicol (2018) 92(1):359–69. doi: 10.1007/s00204-017-2055-1
31. Blake BE, Cope HA, Hall SM, Keys RD, Mahler BW, McCord J, et al. Evaluation of Maternal, Embryo, and Placental Effects in CD-1 Mice following Gestational Exposure to Perfluorooctanoic Acid (PFOA) or Hexafluoropropylene Oxide Dimer Acid (HFPO-DA or GenX). Environ Health Perspect (2020) 128(2):27006. doi: 10.1289/EHP6233
32. Caverly Rae JM, Craig L, Slone TW, Frame SR, Buxton LW, Kennedy GL. Evaluation of chronic toxicity and carcinogenicity of ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate in Sprague-Dawley rats. Toxicol Rep (2015) 2:939–49. doi: 10.1016/j.toxrep.2015.06.001
33. Agency EC. documents heee. ANNEX XV – IDENTIFICATION OF HFPO-DA AND ITS SALTS/ACYL HALIDES AS SVHC. (2019).
34. Coperchini F, Croce L, Pignatti P, Ricci G, Gangemi D, Magri F, et al. The new generation PFAS C6O4 does not produce adverse effects on thyroid cells in vitro. (2020). doi: 10.1007/s40618-020-01466-4
35. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev (2009) 30(4):293–342. doi: 10.1210/er.2009-0002
36. Gore AC. Endocrine-Disrupting Chemicals. JAMA Intern Med (2016) 176(11):1705–6. doi: 10.1001/jamainternmed.2016.5766
37. Coperchini F, Pignatti P, Lacerenza S, Negri S, Sideri R, Testoni C, et al. Exposure to perfluorinated compounds: in vitro study on thyroid cells. Environ Sci Pollut Res Int (2015) 22(3):2287–94. doi: 10.1007/s11356-014-3480-9
38. Song M, Kim YJ, Park YK, Ryu JC. Changes in thyroid peroxidase activity in response to various chemicals. J Environ Monit (2012) 14(8):2121–6. doi: 10.1039/c2em30106g
39. Xin Y, Ren XM, Ruan T, Li CH, Guo LH, Jiang G. Chlorinated Polyfluoroalkylether Sulfonates Exhibit Similar Binding Potency and Activity to Thyroid Hormone Transport Proteins and Nuclear Receptors as Perfluorooctanesulfonate. Environ Sci Technol (2018) 52(16):9412–8. doi: 10.1021/acs.est.8b01494
40. Conti A, Strazzeri C, Rhoden KJ. Perfluorooctane sulfonic acid, a persistent organic pollutant, inhibits iodide accumulation by thyroid follicular cells in vitro. Mol Cell Endocrinol (2020) 515:110922. doi: 10.1016/j.mce.2020.110922
41. Croce L, Coperchini F, Tonacchera M, Imbriani M, Rotondi M, Chiovato L. Effect of long- and short-chain perfluorinated compounds on cultured thyroid cells viability and response to TSH. J Endocrinol Invest (2019) 42(11):1329–35. doi: 10.1007/s40618-019-01062-1
42. Coperchini F, Croce L, Denegri M, Pignatti P, Agozzino M, Netti GS, et al. Adverse effects of in vitro GenX exposure on rat thyroid cell viability, DNA integrity and thyroid-related genes expression. Environ Pollut (2020) 264:114778. doi: 10.1016/j.envpol.2020.114778
43. Dong H, Curran I, Williams A, Bondy G, Yauk CL, Wade MG. Hepatic miRNA profiles and thyroid hormone homeostasis in rats exposed to dietary potassium perfluorooctanesulfonate (PFOS). Environ Toxicol Pharmacol (2016) 41:201–10. doi: 10.1016/j.etap.2015.12.009
44. Conley JM, Lambright CS, Evans N, Strynar MJ, McCord J, McIntyre BS, et al. Adverse Maternal, Fetal, and Postnatal Effects of Hexafluoropropylene Oxide Dimer Acid (GenX) from Oral Gestational Exposure in Sprague-Dawley Rats. Environ Health Perspect (2019) 127(3):37008. doi: 10.1289/EHP4372
45. Zhang S, Guo X, Lu S, Sang N, Li G, Xie P, et al. Exposure to PFDoA causes disruption of the hypothalamus-pituitary-thyroid axis in zebrafish larvae. Environ Pollut (2018) 235:974–82. doi: 10.1016/j.envpol.2018.01.015
46. Kim S, Stroski KM, Killeen G, Smitherman C, Simcik MF, Brooks BW. 8:8 Perfluoroalkyl phosphinic acid affects neurobehavioral development, thyroid disruption, and DNA methylation in developing zebrafish. Sci Total Environ (2020) 736:139600. doi: 10.1016/j.scitotenv.2020.139600
47. Rodríguez-Jorquera IA, Colli-Dula RC, Kroll K, Jayasinghe BS, Parachu Marco MV, Silva-Sanchez C, et al. Blood Transcriptomics Analysis of Fish Exposed to Perfluoro Alkyls Substances: Assessment of a Non-Lethal Sampling Technique for Advancing Aquatic Toxicology Research. Environ Sci Technol (2019) 53(3):1441–52. doi: 10.1021/acs.est.8b03603
48. Mughal BB, Demeneix BA, Fini JB. Evaluating Thyroid Disrupting Chemicals In Vivo Using Xenopus laevis. Methods Mol Biol (2018) 1801:183–92. doi: 10.1007/978-1-4939-7902-8_15
49. Fini JB, Mughal BB, Le Mével S, Leemans M, Lettmann M, Spirhanzlova P, et al. Human amniotic fluid contaminants alter thyroid hormone signalling and early brain development in Xenopus embryos. Sci Rep (2017) 7:43786. doi: 10.1038/srep43786
50. Wang M, Guo W, Gardner S, Petreas M, Park JS. Per- and polyfluoroalkyl substances in Northern California cats: Temporal comparison and a possible link to cat hyperthyroidism. Environ Toxicol Chem (2018) 37(10):2523–9. doi: 10.1002/etc.4239
51. Routti H, Atwood TC, Bechshoft T, Boltunov A, Ciesielski TM, Desforges JP, et al. State of knowledge on current exposure, fate and potential health effects of contaminants in polar bears from the circumpolar Arctic. Sci Total Environ (2019) 664:1063–83. doi: 10.1016/j.scitotenv.2019.02.030
52. Chen J, Zheng L, Tian L, Wang N, Lei L, Wang Y, et al. Chronic PFOS Exposure Disrupts Thyroid Structure and Function in Zebrafish. Bull Environ Contam Toxicol (2018) 101(1):75–9. doi: 10.1007/s00128-018-2359-8
53. Chang YJ, Liu CY, Chiang BL, Chao YC, Chen CC. Induction of IL-8 release in lung cells via activator protein-1 by recombinant baculovirus displaying severe acute respiratory syndrome-coronavirus spike proteins: identification of two functional regions. J Immunol (2004) 173(12):7602–14. doi: 10.4049/jimmunol.173.12.7602
54. Ramhøj L, Hass U, Gilbert ME, Wood C, Svingen T, Usai D, et al. Evaluating thyroid hormone disruption: investigations of long-term neurodevelopmental effects in rats after perinatal exposure to perfluorohexane sulfonate (PFHxS). Sci Rep (2020) 10(1):2672. doi: 10.1038/s41598-020-59354-z
55. Melzer D, Rice N, Depledge MH, Henley WE, Galloway TS. Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. Environ Health Perspect (2010) 118(5):686–92. doi: 10.1289/ehp.0901584
56. Olsen GW, Zobel LR. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch Occup Environ Health (2007) 81(2):231–46. doi: 10.1007/s00420-007-0213-0
57. Olsen GW, Burris JM, Burlew MM, Mandel JH. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J Occup Environ Med (2003) 45(3):260–70. doi: 10.1097/01.jom.0000052958.59271.10
58. Seo SH, Son MH, Choi SD, Lee DH, Chang YS. Influence of exposure to perfluoroalkyl substances (PFASs) on the Korean general population: 10-year trend and health effects. Environ Int (2018) 113:149–61. doi: 10.1016/j.envint.2018.01.025
59. Blake BE, Pinney SM, Hines EP, Fenton SE, Ferguson KK. Associations between longitudinal serum perfluoroalkyl substance (PFAS) levels and measures of thyroid hormone, kidney function, and body mass index in the Fernald Community Cohort. Environ Pollut (2018) 242(Pt A):894–904. doi: 10.1016/j.envpol.2018.07.042
60. Kim MJ, Moon S, Oh BC, Jung D, Ji K, Choi K, et al. Association between perfluoroalkyl substances exposure and thyroid function in adults: A meta-analysis. PloS One (2018) 13(5):e0197244. doi: 10.1371/journal.pone.0197244
61. Byrne SC, Miller P, Seguinot-Medina S, Waghiyi V, Buck CL, von Hippel FA, et al. Exposure to perfluoroalkyl substances and associations with serum thyroid hormones in a remote population of Alaska Natives. Environ Res (2018) 166:537–43. doi: 10.1016/j.envres.2018.06.014
62. Andersson EM, Scott K, Xu Y, Li Y, Olsson DS, Fletcher T, et al. High exposure to perfluorinated compounds in drinking water and thyroid disease. A cohort study from Ronneby, Sweden. Environ Res (2019) 176:108540. doi: 10.1016/j.envres.2019.108540
63. Fisher DA. Fetal thyroid function: diagnosis and management of fetal thyroid disorders. Clin Obstet Gynecol (1997) 40(1):16–31. doi: 10.1097/00003081-199703000-00005
64. Miller MD, Crofton KM, Rice DC, Zoeller RT. Thyroid-disrupting chemicals: interpreting upstream biomarkers of adverse outcomes. Environ Health Perspect (2009) 117(7):1033–41. doi: 10.1289/ehp.0800247
65. Morreale de Escobar G, Obregon MJ, Escobar del Rey F. Role of thyroid hormone during early brain development. Eur J Endocrinol (2004) 151(Suppl 3):U25–37. doi: 10.1530/eje.0.151u025
66. Lyall K, Anderson M, Kharrazi M, Windham GC. Neonatal thyroid hormone levels in association with autism spectrum disorder. Autism Res (2017) 10(4):585–92. doi: 10.1002/aur.1708
67. Rose SR, Brown RS, Foley T, Kaplowitz PB, Kaye CI, Sundararajan S, et al. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics (2006) 117(6):2290–303. doi: 10.1542/peds.2006-0915
68. Simic N, Asztalos EV, Rovet J. Impact of neonatal thyroid hormone insufficiency and medical morbidity on infant neurodevelopment and attention following preterm birth. Thyroid (2009) 19(4):395–401. doi: 10.1089/thy.2008.0282
69. Ballesteros V, Costa O, Iñiguez C, Fletcher T, Ballester F, Lopez-Espinosa MJ. Exposure to perfluoroalkyl substances and thyroid function in pregnant women and children: A systematic review of epidemiologic studies. Environ Int (2017) 99:15–28. doi: 10.1016/j.envint.2016.10.015
70. Preston EV, Webster TF, Oken E, Claus Henn B, McClean MD, Rifas-Shiman SL, et al. Maternal Plasma per- and Polyfluoroalkyl Substance Concentrations in Early Pregnancy and Maternal and Neonatal Thyroid Function in a Prospective Birth Cohort: Project Viva (USA). Environ Health Perspect (2018) 126(2):027013. doi: 10.1289/EHP2534
71. Preston EV, Webster TF, Claus Henn B, McClean MD, Gennings C, Oken E, et al. Prenatal exposure to per- and polyfluoroalkyl substances and maternal and neonatal thyroid function in the Project Viva Cohort: A mixtures approach. Environ Int (2020) 139:105728. doi: 10.1016/j.envint.2020.105728
72. Inoue K, Ritz B, Andersen SL, Ramlau-Hansen CH, Høyer BB, Bech BH, et al. Perfluoroalkyl Substances and Maternal Thyroid Hormones in Early Pregnancy; Findings in the Danish National Birth Cohort. Environ Health Perspect (2019) 127(11):117002. doi: 10.1289/EHP5482
73. Liew Z, Luo J, Nohr EA, Bech BH, Bossi R, Arah OA, et al. Maternal Plasma Perfluoroalkyl Substances and Miscarriage: A Nested Case-Control Study in the Danish National Birth Cohort. Environ Health Perspect (2020) 128(4):47007. doi: 10.1289/EHP6202
74. Aimuzi R, Luo K, Huang R, Huo X, Nian M, Ouyang F, et al. Perfluoroalkyl and polyfluroalkyl substances and maternal thyroid hormones in early pregnancy. Environ Pollut (2020) 264:114557. doi: 10.1016/j.envpol.2020.114557
75. Itoh S, Araki A, Miyashita C, Yamazaki K, Goudarzi H, Minatoya M, et al. Association between perfluoroalkyl substance exposure and thyroid hormone/thyroid antibody levels in maternal and cord blood: The Hokkaido Study. Environ Int (2019) 133(Pt A):105139. doi: 10.1016/j.envint.2019.105139
76. Lebeaux RM, Doherty BT, Gallagher LG, Zoeller RT, Hoofnagle AN, Calafat AM, et al. Maternal serum perfluoroalkyl substance mixtures and thyroid hormone concentrations in maternal and cord sera: The HOME Study. Environ Res (2020) 185:109395. doi: 10.1016/j.envres.2020.109395
77. Reardon AJF, Khodayari Moez E, Dinu I, Goruk S, Field CJ, Kinniburgh DW, et al. Longitudinal analysis reveals early-pregnancy associations between perfluoroalkyl sulfonates and thyroid hormone status in a Canadian prospective birth cohort. Environ Int (2019) 129:389–99. doi: 10.1016/j.envint.2019.04.023
78. Xiao C, Grandjean P, Valvi D, Nielsen F, Jensen TK, Weihe P, et al. Associations of Exposure to Perfluoroalkyl Substances With Thyroid Hormone Concentrations and Birth Size. J Clin Endocrinol Metab (2020) 105(3):735–45. doi: 10.1210/clinem/dgz147
79. Luo J, Xiao J, Gao Y, Ramlau-Hansen CH, Toft G, Li J, et al. Prenatal exposure to perfluoroalkyl substances and behavioral difficulties in childhood at 7 and 11 years. Environ Res (2020) 191:110111. doi: 10.1016/j.envres.2020.110111
80. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci (2007) 99(2):366–94. doi: 10.1093/toxsci/kfm128
81. Zhang T, Sun H, Qin X, Gan Z, Kannan K. PFOS and PFOA in paired urine and blood from general adults and pregnant women: assessment of urinary elimination. Environ Sci Pollut Res Int (2015) 22(7):5572–9. doi: 10.1007/s11356-014-3725-7
82. Tahboub R, Arafah BM. Sex steroids and the thyroid. Best Pract Res Clin Endocrinol Metab (2009) 23(6):769–80. doi: 10.1016/j.beem.2009.06.005
83. Gump BB, Wu Q, Dumas AK, Kannan K. Perfluorochemical (PFC) exposure in children: associations with impaired response inhibition. Environ Sci Technol (2011) 45(19):8151–9. doi: 10.1021/es103712g
84. Hoffman K, Webster TF, Weisskopf MG, Weinberg J, Vieira VM. Exposure to polyfluoroalkyl chemicals and attention deficit/hyperactivity disorder in U.S. children 12-15 years of age. Environ Health Perspect (2010) 118(12):1762–7. doi: 10.1289/ehp.1001898
85. Stein CR, Savitz DA. Serum perfluorinated compound concentration and attention deficit/hyperactivity disorder in children 5-18 years of age. Environ Health Perspect (2011) 119(10):1466–71. doi: 10.1289/ehp.1003538
86. Oulhote Y, Steuerwald U, Debes F, Weihe P, Grandjean P. Behavioral difficulties in 7-year old children in relation to developmental exposure to perfluorinated alkyl substances. Environ Int (2016) 97:237–45. doi: 10.1016/j.envint.2016.09.015
87. Vuong AM, Braun JM, Yolton K, Wang Z, Xie C, Webster GM, et al. Prenatal and childhood exposure to perfluoroalkyl substances (PFAS) and measures of attention, impulse control, and visual spatial abilities. Environ Int (2018) 119:413–20. doi: 10.1016/j.envint.2018.07.013
88. Liew Z, Olsen J, Cui X, Ritz B, Arah OA. Bias from conditioning on live birth in pregnancy cohorts: an illustration based on neurodevelopment in children after prenatal exposure to organic pollutants. Int J Epidemiol (2015) 44(1):345–54. doi: 10.1093/ije/dyu249
89. Ode A, Källén K, Gustafsson P, Rylander L, Jönsson BA, Olofsson P, et al. Fetal exposure to perfluorinated compounds and attention deficit hyperactivity disorder in childhood. PloS One (2014) 9(4):e95891. doi: 10.1371/journal.pone.0095891
90. Long M, Ghisari M, Kjeldsen L, Wielsøe M, Nørgaard-Pedersen B, Mortensen EL, et al. Autism spectrum disorders, endocrine disrupting compounds, and heavy metals in amniotic fluid: a case-control study. Mol Autism (2019) 10:1. doi: 10.1186/s13229-018-0253-1
91. Lyall K, Yau VM, Hansen R, Kharrazi M, Yoshida CK, Calafat AM, et al. Prenatal Maternal Serum Concentrations of Per- and Polyfluoroalkyl Substances in Association with Autism Spectrum Disorder and Intellectual Disability. Environ Health Perspect (2018) 126(1):017001. doi: 10.1289/EHP1830
92. Fei C, Olsen J. Prenatal exposure to perfluorinated chemicals and behavioral or coordination problems at age 7 years. Environ Health Perspect (2011) 119(4):573–8. doi: 10.1289/ehp.1002026
93. Lien GW, Huang CC, Shiu JS, Chen MH, Hsieh WS, Guo YL, et al. Perfluoroalkyl substances in cord blood and attention deficit/hyperactivity disorder symptoms in seven-year-old children. Chemosphere (2016) 156:118–27. doi: 10.1016/j.chemosphere.2016.04.102
94. Liew Z, Ritz B, Bach CC, Asarnow RF, Bech BH, Nohr EA, et al. Prenatal Exposure to Perfluoroalkyl Substances and IQ Scores at Age 5; a Study in the Danish National Birth Cohort. Environ Health Perspect (2018) 126(6):067004. doi: 10.1289/EHP2754
95. Vuong AM, Yolton K, Xie C, Dietrich KN, Braun JM, Webster GM, et al. Prenatal and childhood exposure to poly- and perfluoroalkyl substances (PFAS) and cognitive development in children at age 8 years. Environ Res (2019) 172:242–8. doi: 10.1016/j.envres.2019.02.025
96. Høyer BB, Bonde JP, Tøttenborg SS, Ramlau-Hansen CH, Lindh C, Pedersen HS, et al. Exposure to perfluoroalkyl substances during pregnancy and child behaviour at 5 to 9years of age. Horm Behav (2018) 101:105–12. doi: 10.1016/j.yhbeh.2017.11.007
Keywords: perfluorinated alkylated substances, perfluorinated alkylated substances alternatives, endocrine disruptor, perfluorooctanoic acid and perfluorooctane sulfonic acid, thyroid, hypothyroidism, GenX, pregnancy
Citation: Coperchini F, Croce L, Ricci G, Magri F, Rotondi M, Imbriani M and Chiovato L (2021) Thyroid Disrupting Effects of Old and New Generation PFAS. Front. Endocrinol. 11:612320. doi: 10.3389/fendo.2020.612320
Received: 30 September 2020; Accepted: 04 December 2020;
Published: 19 January 2021.
Edited by:
Noriyuki Koibuchi, Gunma University, JapanReviewed by:
Winda Ariyani, Gunma University, JapanKingsley Ibhazehiebo, University of Calgary, Canada
Copyright © 2021 Coperchini, Croce, Ricci, Magri, Rotondi, Imbriani and Chiovato. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Luca Chiovato, bHVjYS5jaGlvdmF0b0BpY3NtYXVnZXJpLml0